Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Pancreatic Cancer Panel Human

  • Regulatory status:RUO
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD11462100CS 96 wells (1 kit)
PubMed Product Details
Technical Data

Sample Requirements

80 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box)

Calibration Range

MMP-7: 15.63 – 16,000 pg/ml
GDF-15: 4.38 – 4,480 pg/ml
Midkine: 4.88 – 5,000 pg/ml

Summary

Features

  • It is intended for research use only
  • The kit consists of 2 assays
  • The Pancreatic Cancer Assay 1 measures human MMP-7 and GDF-15 in serum
  • The Pancreatic Cancer Assay 2 measures human Midkine in serum
  • Additional sample types may be suitable but have not been validated
  • The total assay time is less than 1.5 hours
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Oncology

Summary

Matrix metalloproteinases (MMPs) constitute a family of structurally related zinc-dependent endopeptidases capable of degrading basement membrane and all components of the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) inhibit the proteolytic activity of MMPs.
MMPs perform multiple roles including tissue remodeling, repair, and modulation of immune responses. In healthy tissues, MMPs are rarely expressed. Excessive MMP production has been reported in diverse inflammatory conditions such as cancer, chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, arthritis, and atherosclerosis. It has been linked to the development of metastases and is also considered to play a role in tumorigenesis and tumor progression.
MMP-7 is a 28 kDa protein consisting of 250 amino acids. MMP-7 has been found to be over-expressed in several tumors, such as those associated with esophageal, cholangiocarcinoma, gastric, colon, prostate and bladder cancer. The overexpression of MMP-7 is significantly associated with metastasis and the 1-year survival rate in pancreatic cancer. Saarialho-Kere et al. (1996) have reported enhanced expression of MMP-7 in gastrointestinal ulcers, suggesting a significant role in epithelial remodelling occurring in gastrointestinal ulcerations. Matsuno et al. (2003) have reported that MMP-7 appears to be expressed only in the epithelial cells on the edge of ulcers and indicates the degree of inflammation in ulcerative colitis.

Growth differentiation factor 15 (GDF-15) is a member of the transforming growth factor b
(TGF-b) cytokine superfamily. GDF-15 was originally cloned as macrophage-inhibitory cytokine 1 (MIC-1) and later also identified as placental TGF-b, placental bone morphogenetic protein (PLAB), nonsteroidal anti-inflammatory drug-activated gene 1, and prostate-derived factor. GDF-15 is synthesized as a 62-kDa precursor protein, then cleavage and secreted as 25-kDa disulfide-linked dimmer.
GDF-15 is produced in low amounts under baseline conditions in most tissues such as brain, liver, kidney, pancreas, but not normally in many other organs including the heart. It is highly expressed in placenta and moderately in prostate. GDF-15 is also upregulated by other cardiovascular events triggering oxidative stress, including pressure overload, and atherosclerosis. Serum GDF-15 concentrations increase in maternal serum with advancing gestation in normal pregnancy.
Increased GDF-15 expression has been documented in a variety of epithelial cell lines, including breast, pancreas, colorectal, and prostate cancers. Microarray studies have revealed increased expression of GDF-15 in patients with breast cancer, and serum GDF-15 levels are the best single predictor of the presence of pancreatic carcinoma. In the case of prostate cancer, serum GDF-15 levels increase with progression of disease to metastasis. In colon cancer, increasing GDF-15 expression is associated with the progression of colonic adenomas to invasive cancer and subsequent metastasis, with serum levels at presentation being an independent predictor of subsequent disease-free status and overall survival.

Midkine (MK, also called neurite growth promoting factor 2, NEGF-2), a product of a retinoic acid responsive gene, is a secreted 13 kDa protein belonging to the family of heparin binding growth/differentiation factors. Midkine is composed of two domains held together by disulfide linkages. The C-terminally located domain contains two heparin binding sites and is usually responsible for midkine activity. Part of the MK activity is enhanced by dimerization of MK.
Midkine has been found in vertebrates from human to zebrafish and is most strongly expressed
in midgestation. In the adult MK expression is restricted. In addition to normal development, MK is also involved in the pathogenesis of diseases, e.g. inflammatory diseases, human carcinomas such as esophageal, stomach, colon, pancreatic, thyroid, lung, urinary, hepatocellular, neuroblastoma, glioblastoma, Wilm´s tumor etc. High MK levels are associated with poor prognosis in some types of cancer. The increased expression in many carcinomas indicates that MK can be applied to the diagnosis of malignancy. Midkine is expressed during the reparative stage of bone fractures, also supresses infection of cells by some viruses including HIV. Anti-apoptotic and cell protecting activity of midkine makes it promising in therapy.

Clinical use and areas of investigation :

  • Colorectal cancer
  • Pancreatic cancer
  • Bladder cancer
  • Oncology
  • Hematology
  • Cardiology
  • Pregnancy
  • Inflammatory diseases
  • Preservation and repair of injured tissues
References to Summary

References to Pancreatic Cancer Panel

  • Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006 Feb 17;98 (3):294-7
  • Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997 Oct 14;94 (21):11514-9
  • Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003 Jul;9 (7):2642-50
  • Callebaut C, Nisole S, Briand JP, Krust B, Hovanessian AG. Inhibition of HIV infection by the cytokine midkine. Virology. 2001 Mar 15;281 (2):248-64
  • Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997 May 1;57 (9):1814-9
  • Gunes M, Kemik AS, Pirincci N, Gecit I, Taken K, Yuksel MB, Kaba M, Eryilmaz R. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients. Asian Pac J Cancer Prev. 2013;14 (2):873-6
  • Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res. 2007 Oct 1;13 (19):5825-33
  • Ikematsu S, Nakagawara A, Nakamura Y, Sakuma S, Wakai K, Muramatsu T, Kadomatsu K. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer. 2003 May 19;88 (10):1522-6
  • Ikematsu S, Okamoto K, Yoshida Y, Oda M, Sugano-Nagano H, Ashida K, Kumai H, Kadomatsu K, Muramatsu H, Takashi Muramatsu, Sakuma S. High levels of urinary midkine in various cancer patients. Biochem Biophys Res Commun. 2003 Jun 27;306 (2):329-32
  • Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, Okamoto K, Oda M, Sakuma S, Aikou T, Muramatsu H, Kadomatsu K, Muramatsu T. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 2000 Sep;83 (6):701-6
  • Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007 Feb 15;13 (4):1133-9
  • Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007 Feb;53 (2):284-91
  • Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, Hirao Y, Muramatsu T, Kadomatsu K. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology. 1999 Oct;57 (3):253-7
  • Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 2003 Aug 15;63 (16):5034-40
  • Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier ML, Russell PK, Salamonsen LA, Wallace EM, Breit SN. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab. 2000 Dec;85 (12):4781-8
  • Park HD, Kang ES, Kim JW, Lee KT, Lee KH, Park YS, Park JO, Lee J, Heo JS, Choi SH, Choi DW, Kim S, Lee JK, Lee SY. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics. 2012 Dec;12 (23-2
Related Products Docs